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Abstract
Survival data with nonnegligible cure fractions are commonly encountered in
clinical cancer clinical research. Recently, several authors (e.g. Kuk and Chen,
1992; Maller and Zhou, 1993; Peng and Dear, 2000; Sy and Taylor, 2000) have
proposed to use semiparametric cure models to analyze such data. Much of the
existing work has been emphasized on cure detections and regression techniques.
In contrast, this project focuses on the hypothesis testing in the presence of a cure
fraction. Specically, our interest lies in detecting whether there exists survival
dierences among non-cured patients between treatment arms. For this purpose,
we investigate the use of a modied Cramer-von Mises statistic for two-sample
survival comparisons within the framework of cure models. Such a test has
been studied by Tamura et al. (2000) using a bootstrap procedure. We
will focus on developing asymptotic theory and convergent algorithms
in this paper. We show that the limiting distributions of the Cramer-von Mises
statistic under the null hypothesis can be represented by stochastic integrals and a
weighted noncentral chi-squares. Both representations lead to concrete numerical
schemes for computing the limiting distributions. The algorithms can be eas-
ily implemented for data analysis and signicantly reduce computing time
compared to the bootstrap approach. For illustrative purposes, we apply the
proposed test to a published clinical trial.
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1 Introduction
In cancer trials the idea of \cure from cancer" is that the disease would be completely elim-
inated so that it never recurs, and the patient's lifespan is the same as that of someone who
has never suered cancer. Treatments are typically developed to increase patients' chances of
being cured, but considerable interest has also been given to pursue treatments that prolong
survival among non-cured patients as well. Because the study population is essentially an
unobservable mixture of patients deemed curable and non-curable, evaluation of treatment
eects in such a scenario is often complicated. A recently published study is presented below
as an illustrative example.
Between 1992 and 1999, a phase III clinical trial was conducted by Adelstein et
al. (2003) of the Eastern Cooperative Oncology Group (ECOG) to evaluate treat-
ment eects in patients with unresectable head and neck cancer. Patients were
randomized among the following treatment arms: a standard single daily fraction-
ated radiotherapy (control arm), and a split course of single daily fractionated
radiotherapy and chemotherapy (experimental arm). One primary endpoint was
whether these treatments had survival benet in terms of preventing death from
head and neck cancer. In this trial, a number of long term survivors have been
observed. But, in addition to the comparison of the cure rates, the investigators
were also interested in evaluating the treatment eect in terms of survival among
patients who were not cured.
The concept of cure brings new clinical interests as well as statistical challenges. For
instance, clinical objectives are not only focused on the comparison of unconditional distribu-
tions of the time to a medical event of interest (e.g. death), but also on that of the conditional
distributions within non-cured patients (e.g. Berkson and Gage, 1952; Farewell, 1982; Green-
house and Wolfe, 1984; Gray and Tsiatis, 1989; Laska and Meisner, 1992). Meanwhile, other
characteristic problems in survival analysis need to be addressed. For example, random ac-
crual and patients' dropout or loss to follow up are to be modeled through random right
censoring processes. Several authors (e.g. Kuk and Chen, 1992; Peng and Dear, 2000; Sy and
1
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Taylor, 2000) have proposed using semiparametric cure models to analyze such data, with
emphasis placed on regression modeling. A complete review of the statistical methods using
censored failure time to determine the presence of a cure fraction can be seen in Maller and
Zhou (1992, 1993).
In this article, we will take a dierent perspective by focusing on the characterization of the
conditional distribution among non-cured individuals. That is, we are interested in studying
the distribution of the time-to-event variables given the event (e.g. disease-related death) will
occur before a clinically meaningful terminal time  . Explanations of these types of models
from medical viewpoints, together with some available statistical methods (e.g. likelihood
ratio tests and rank tests) can be found in, for example, Laska and Meisner (1992) and Gray
and Tsiatis (1989), and the likelihood ratio test has been used to analyze a clinical trial (Laska,
Siegel and Sunshine, 1991).
Indeed, the past two decades has seen a rapid development of statistical tools for detecting
survival dierences in clinical trials, but log-rank type tests, most powerful under proportional
hazards alternatives, are routinely performed by practitioners in the absence of cure fractions.
Schumacher (1984), however, demonstrated via simulation that Cramer-von Mises statistics
have decent power under proportional hazards alternatives and are superior to log-rank tests
in other cases. A Cramer-von Mises type statistic was proposed by Tamura, Faries,
and Feng (2000) for a two-sample survival comparison within the framework of
cure models, and inference was drawn via bootstrap simulations. On the other hand,
in the absence of cure fractions the asymptotic theory of the Cramer-von Mises type statistic
for one-sample comparisons under particular parametric models has been intensively inves-
tigated by Koziol and Green (1976) (with censoring) and Stute (1997) (without censoring).
This article investigates the use of the Cramer-von Mises statistic for two-sample comparisons
in the presence of censoring and cure fractions. Moreover, we develop the asymptotic theory in
a more general framework: unlike in Koziol and Green (1976), our procedure does not require
the specication of the censoring distributions. We also give concrete numerical algorithms for
practical applications without resorting to resampling schemes. Though both deal with sur-
vival comparisons for cure models, our motivation diers from that of Gray and Tsiatis (1989)
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in that their main interest was in testing dierences in cure rates, while we are primarily in-
terested in testing dierences in survival among non-cured patients. In contrast to Tamura
et al (2000), we further the asymptotic theory: not only do we give two charac-
terizations of the limit distribution in detail (one of which appeared sketchily in
Tamura et al. (2000) as well), but also we construct practically usable algorithms
based on them. As our simulation results (in Section 6) indicate, the proposed
algorithms signicantly reduce computing time compared to the bootstrap pro-
cedure. In addition, the involved techniques may have applications elsewhere, for
example, numerically performing Loeve principle component decomposition of a
complex stochastic process.
The rest of the article is structured as follows. We state a general cure model in Section
2, and formulate a two-sample comparison hypothesis in Section 3. We introduce in Section 4
a modied version of Cramer-von Mises statistic, and derive its large sample properties, and
give in Section 5 two numerical simulation schemes for constructing the limiting distributions
of the Cramer-von Mises statistics. We conduct simulation studies in Section 6 to examine
the nite sample performance of the proposed two algorithms, and illustrate the use of the
Cramer-von Mises statistics by analyzing a published clinical trial in head and neck cancer in
Section 7. We conclude this article with general discussion in Section 8. In the Appendix, we
give the technical proofs to the main theorems, and include a convergence result on stochastic
integrals, which has largely facilitated our proofs.
Throughout this article, F (t) = P (T  t) denotes the distribution for a nonnegative
random variable T , X
n
) X means random variables X
n
converge to X in distribution,
X
n
! X means the convergence is in probability, X
D
= Y means random variables X and Y
are equally distributed, and for any real function g(), g(1 ) means lim
x!1;x6=1
g(x) if the
limit exists.
3
Hosted by The Berkeley Electronic Press
2 A General Cure Model
Let T be a nonnegative random variable of interest, for example, the time from the start of
treatment to disease-related death in our motivating example. We assume that its distribution
on the extended real line [0;+1], where +1 is identied to be a single point, is given by
F (dt)  PfT 2 (t; t+ dt]g = pf(t)dt + qÆ
1
(dt); p; q > 0; p+ q = 1;
where f  0;
R
1
0
f(t)dt = 1, q (or p) is the cure (or non-cure) proportion, and for any a 2
[0;+1]; Æ
a
() is a counting measure with a point mass on a. This is equivalent to saying that
T follows a mixed distribution with a dominating measure consisting of a Lebesgue measure
and a singular point mass placed at +1. In reality it would be a reasonable assumption that
the probability density f , corresponding to the non-cure proportion of T , have a compact
support [0;  ]  [0;1), and
 = infft  0 : sup
st
f(s) = 0g <1: (1)
For instance, if a disease-related death did not occur to a patient after a long time of observa-
tion, say roughly, 5 years in a head and neck cancer clinical trial, it would be \safe" to predict
that patient would not die from this cancer. Similar formulations for this type of cure models
can be found in Maller and Zhou (1992, 1993) and Peng and Dear (2000), among others.
We can either directly identify the  , the clinically meaningful terminal time, with available
medical knowledge or estimate it from empirical data. Specically, denote by
^
F the Kaplan-
Meier estimate for the distribution function F and note that (1) is equal to
 = infft  0 : F (t) = F (1 )g; (2)
then  can be consistently estimated by
^ = infft > 0 :
^
F (t) =
^
F (1 )g; (3)
which is the turning point after which the estimated distribution curve becomes plateau, and is
indeed the largest uncensored failure time (Maller and Zhou, 1992). Elementary probabilistic
4
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arguments immediately imply that ^   almost surely. Hence, by (3) and the monotonicity
of
^
F ,
^
F (^) =
^
F () =
^
F (1 )
almost surely.
Both (1) and (3) indicate that  can be identied and estimated from F , as a function of
f and p. Additionally, since estimating and testing f or p is of major interest to us, we will
focus only on these two parameters (and not ) in this article; a detailed discussion on  and
its estimation can be found in Maller and Zhou (1992).
3 Two-Sample Comparison of Cure Models
Large-scale clinical trials, for example, phase III trials, are often designed to detect survival
benets among competitive regimen, and two-sample comparisons are frequently utilized. In
what follows, we study the Cramer-von Mises type statistic for comparing two treatments in
a clinical trial.
The notation below is similar to that in the general cure model, except that we use an
additional subscript i to indicate treatment. Specically, we denote the time-to-event variables
by T
ij
 F
i
, i = 1; 2; j = 1; : : : ; n
i
; where, for example, i = 1 corresponds to the control arm
and i = 2 to the experimental arm, F
i
s are distribution functions, and j refers to the j-
th patient in his respective treatment arm; we also assume the nonnegative censoring times
U
ij
 G
i
where G
i
s are distribution functions. We further assume that the fT
ij
; U
ij
: i =
1; 2; j = 1; : : : ; n
i
g are all independent. Because of censoring, we observe V
ij
= T
ij
^ U
ij
and
Æ
ij
= I(T
ij
 U
ij
). If our interest were in estimating and comparing the F
i
; (i = 1; 2); we
would use standard methods for right censored data, such as the Kaplan-Meier estimators
or the log-rank type statistics. However, the distributions of more direct interest are two
conditional distributions F

i
(t) = P (T
ij
 tjT
ij
< 1); i = 1; 2. To explore how to compare
these conditional distributions, rst let
F
i
(t)  P (T
ij
 t) = p
i
Z
t
0
f
i
(s)ds+ q
i
I(t =1); p
i
+ q
i
= 1; 0 < p
i
; q
i
< 1:
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Then,
F

i
(t) =
Z
t
0
f
i
(s)ds = p
 1
i
F
i
(t):
For a two-sample comparison, the statistical test is formulated as
H
0
: F

1
= F

2
vs H
1
: F

1
6= F

2
: (4)
We assume both f
i
s have compact support 
i
 infft  0 : sup
st
f
i
(s) = 0g <1; and denote
 = maxf
1
; 
2
g such that [0;  ] covers the supports of both f
1
and f
2
. Moreover, we assume
that
P (U
11
> ) > 0; P (U
21
> ) > 0; (5)
so that  can be observed with a positive probability in both treatment arms.
As is the case without cure fractions, if it is reasonable to believe that F

1
(t)  F

2
(t) (or
vice versa), H
1
should be replaced by a one-sided hypothesis. Furthermore, if the proportional
hazard assumption is approximately satised, a log-rank type statistic, powerful in detecting
the stochastic dominance, should perform better than its Cramer-von Mises counterpart.
However, without such a proportionality assumption, the Cramer-von Mises type statistic,
which is particularly useful in detecting the deviation of two distributions, is more appropriate
(see, e.g. Schumacher, 1984).
4 Cramer-von Mises Statistic and its Asymptotics Prop-
erties
Let n
1
and n
2
be the sample size of two arms, respectively, and n = n
1
+ n
2
. Following Laska
and Meisner (1992), for each i = 1; 2, we derive a nonparametric maximum likelihood estimate
of F

i
based on the observed data (V
ij
; Æ
ij
); j = 1; : : : ; n, as
^
F

i
(t) = p^
i
 1
^
F
i
(t);
where
^
F
i
(t) is the usual Kaplan-Meier estimator for the F
i
and p^
i
=
^
F
i
(1 ) is the consistent
estimate for p
i
, the estimated non-cure fraction in the i-th arm (see, Maller and Zhou, 1992).
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Denote the pooled conditional distribution by
^
F

pool
=
n
1
p^
1
^
F

1
+ n
2
p^
2
^
F

2
n
1
p^
1
+ n
2
p^
2
:
To test H
0
in (4), we dene a modied version of Cramer-von Mises statistic to measure the
discrepancy between the two empirical distributions
^
F

1
() and
^
F

2
() as follows
W
n
= n
Z
1
0
f
^
F

1
(t ) 
^
F

2
(t )g
2
d
^
F

pool
(t): (6)
The following theorem gives the asymptotic distribution of W
n
, under H
0
: F

1
= F

2
= F

:
Theorem 1 Assume that n
1
=n! . Then under the null hypothesis, the Cramer-von Mises
statistic,
W
n
) X =
Z
1
0
G
2
(t )dF

(t);
where the Gaussian process G is (distributionally) uniquely dened by
G(t) =
1
p

h
1  p
1
F

(t)
p
1
W
1
fc
1
(t)g   F

(t)
q
1
p
1
W
1
fc
1
(1 )g
i
 
1
p
1  
h
1  p
2
F

(t)
p
2
W
2
fc
2
(t)g   F

(t)
q
2
p
2
W
2
fc
2
(1 )g
i
;
W
1
() and W
2
() are independent Brownian motions and
c
i
(t) =
Z
t
0
p
i
dF

(s)

i
(s)f1  p
i
F

(s )g
:
Here 
i
(s) = P (V
ij
 s) = f1 G
i
(s )gf1  p
i
F

(s )g for i = 1; 2.
Remark: The validity of this theorem requires, c
i
(t); i = 1; 2, the changes of time in the
Gaussian processes, be nite over [0;1). For each i = 1; 2, because c
i
(t) is non-decreasing
we only need to show the niteness of c
i
(1 ). In fact, if  < 1 as assumed and under (5),
c
i
(1 ) = c
i
(
i
) <1.
The proof relies on large sample results of the Kaplan-Meier product limit estimator and
can be found in Tamura et al. (2000). Asymptotic results of the Kaplan-Meier estimates
have been proved by Breslow and Crowley (1974), Gill (1984), and Fleming and Harrington
(1991) in various degrees of generalization.
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We note in this theorem the null distribution F

is left unspecied, but it can be replaced
by its empirical estimate
^
F

pool
when approximating the distribution of X under the null
hypothesis; see Algorithm 1 and the associated large sample result (Theorem 4) in Section 5.
For gaining additional insight into the limiting distribution of the Cramer-von Mises statis-
tics under H
0
, we consider a Loeve type expansion in terms of principal components. Speci-
cally, we represent the X in Theorem 1 as a mixture of noncentral 
2
, which would facilitate
numerical realizations. Similar results in the context of non-censored data or censored data
without cured fraction are available, see for example Durbin et al. (1972, 1975) and Chapter
5 of Shorack and Wellner (1986). With some modications, the arguments in these references
would apply in the new context of cure models for establishing the existence of such decom-
positions. However, as is frequently the case in practice, the diÆculty for making use of these
results lies in the computation of the associated eigenvalues (e.g. the 
k
s below). By focusing
on some special classes of parameterized distributions (of both survival and censoring times),
the aforementioned references have obtained closed-form eigenvalues. But, in more general
scenarios (e.g. censored data with a cure fraction as we have) we would not expect such
explicit formulae to exist. Therefore, we approach this issue from a numerical perspective
by deriving the kernel function for the principal component decomposition in more general
situations, where the distribution functions for both survival and censoring times are left un-
specied. Based on this decomposition, a numerical algorithm is developed in Section 5 for
computing the associated eigenvalues.
By exploiting the independence ofW
1
() andW
2
(), we can compute the covariance function
K(s; t) of the Gaussian process G(). Specically,
K(s; t) = EfG(s)G(t)g = 
 1
fa
1
(s; t)c
1
(s ^ t) + b
1
(s; t)c
1
()  d
1
(s; t)c
1
(t)  d
1
(t; s)c
1
(s)g
+(1  )
 1
fa
2
(s; t)c
2
(s ^ t) + b
2
(s; t)c
2
()  d
2
(s; t)c
2
(t)  d
2
(t; s)c
2
(s)g (7)
where
a
i
(s; t) = p
 2
i
f1 p
i
F

(t)gf1 p
i
F

(s)g; b
i
(s; t) = p
 2
i
q
2
i
F

(t)F

(s); d
i
(s; t) = p
 2
i
q
i
f1 p
i
F

(t)gF

(s)
for i = 1; 2. The result is summarized in the following theorem, whose proof can be found in
the Appendix.
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Theorem 2 The distribution for the limiting random variable X in Theorem 1 can be repre-
sented as the following noncentral 
2
X
D
=
1
X
k=1

k
Z
2
k
(8)
where Z
k
are i.i.d. standard normal random variables and 
k
are the eigenvalues of a symmet-
ric compact positive linear operator T on Hilbert space

L
2
([0;1]); (; )

with inner product
(f; g) =
R

0
f(s)g(s)F

(ds),
(T f)(t) =
Z
1
0
K(s; t)f(s)F

(ds):
Again, without loss of generality, we may assume the 
k
are decreasing in k to zero.
After identifying elements by their equivalence classes,

L
2
([0;1]); (; )

=

L
2
([0;  ]); (; )

.
In practice, unless some strong parametric assumptions are made, numerical computation of
the 
k
s will typically involve in matrix approximation of the integral operator T , which has
F

as an integrator. A direct discretization for T on interval [0;  ] with uniform mesh size
may cause numerical instability. Through a change of variables, we can convert the eigenvalue
problem for T in the space

L
2
([0;  ]); (; )

to an equivalent eigenvalue problem for operator
~
T in the Hilbert space on the unit interval

L
2
([0; 1]); h; i

, wherein the inner product is
h
~
f; ~gi =
R
1
0
~
f(r)~g(r)dr for
~
f; ~g 2 L
2
([0; 1]). We give in the Appendix the explicit form of
~
T and the justication that these two operators have the same set of eigenvalues on each
individual Hilbert space. Hence, for numerical stability, our numerical scheme (outlined in
Section 5) will be based on the transformed operator
~
T . In particular, assuming that F

is
strictly increasing and absolutely continuous and letting
(
~
T ~g)(
~
t) =
Z
1
0
~
K(~s;
~
t)~g(~s)d~s
for any ~g 2 L
2
([0; 1]), where
~
K is as dened in (14), one may show in the Appendix that the 
k
are also eigenvalues for the integral operator
~
T . The 
k
's can be computed more conveniently
from operator
~
T than from operator T directly.
The representation of X in (8) implies that the shape of distribution should be similar
to that of the 
2
. We conrm this by a numerical approximation in our data example later.
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Koziol and Green (1976) considered a very special case (in the absence of cure fractions) with
n
1
= n
2
; p
1
= p
2
= 1; F (t) = F

(t) being uniform on [0; 1] and 1   G
1
(t) = 1   G
2
(t) =
(1   t)

;  < 2. In such a case c
1
(t) = c
2
(t) = 1   (1   t)
 (1+)
and the covariance function
K(s; t) has a simple form: K(s; t) = 4(1  s)(1  t)f1  (1  s^ t)
 (1+)
g: They computed the

i
explicitly and gave some useful reference tables.
We will develop an approximation algorithm (Algorithm 2 in Section 5) to calculate these
eigenvalues for more general and practical settings, where the null distribution F

and the
censoring distributions G
i
are unspecied, and, hence, functions such as 
i
(s) and c
i
(s) in
the limiting distribution are unknown. In particular, we consistently estimate these unknown
quantities by
^
i
(s) = 1 
1
n
i
n
i
X
j=1
I(V
ij
< s); (9)
and
c^
i
(t) =
Z
t
0
d
^
F
i
(s)
^
i
(s )f1 
^
F
i
(s )g
; (10)
for i = 1; 2 and use them to replace 
i
; c
i
in the kernels K and
~
K. We justify the use of (9)
and (10) with the following theorem, whose proof is given in the Appendix.
Theorem 3 c^
i
consistently estimates c
i
. That is, c^
i
! c
i
in probability on D[0;  ] and this
convergence is in conjunction with that of p^
i
to p
i
and
^
F
i
(t) to F
i
(t).
5 Numerical Approximation/ Simulation Schemes
In this section we develop two \data driven" numerical schemes to construct random variables
that approximate the limiting distribution of the Cramer-von Mises statistics. We start with
estimating   maxf
1
; 
2
g by ^ = maxf^
1
; ^
2
g; where ^
i
= infft  0 :
^
F
i
(t) =
^
F
i
(1 )g: We
rst present a numerical algorithm based on the stochastic integral representation theorem
(Theorem 1) (see also Remark 2 of Tamura et al. (2000)), followed by a numerical scheme
based on the principal decomposition theorem (Theorem 2). The associated limit theorems
are also provided.
Algorithm 1: An approximation scheme based on Theorem 1
10
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1. Compute statistics ^
i
in (9), c^
i
in (10), p^
i
; for i = 1; 2, and
^
F

pool
.
2. For each positive integerm; generate i.i.d standard normal random variables 
1
; : : : ; 
m

N(0; 1) and 
1
; : : : ; 
m
 N(0; 1); dene
W
m;n
1
(t) =
[tm=^ ]
X
k=1
fc^
1
(k^=m)  c^
1
((k   1)^=m)g
1=2

k
and
W
m;n
2
(t) =
[tm=^ ]
X
k=1
fc^
2
(k^=m)  c^
2
((k   1)^=m)g
1=2

k
;
3. Let
G
m;n
(t) =
1
p

n
1  p^
1
^
F

pool
(t)
p^
1
W
m;n
1
(t) 
^
F

pool
(t)
q^
1
p^
1
W
m;n
1
(^)
o
 
1
p
1  
n
1  p^
2
^
F

pool
(t)
p^
2
W
m;n
2
(t) 
^
F

pool
(t)
q^
2
p^
2
W
m;n
2
(^)
o
4. Finally, compute
X
m;n
=
Z
^
0
G
2
m;n
(t )d
^
F

pool
(t):
Note that m is the size of the approximation scheme and n is the size of the real clinical trial
dataset. Since every integral appearing in the above scheme has a piece-wise constant inte-
grand, these integrals are eectively nite summations. In practice, we shall repeatedly
apply this algorithm to obtain a series of independent realizations of X
m;n
in order
to approximate the asymptotic distribution. Indeed, the following theorem, proved in
the Appendix, shows the convergence in distribution of X
m;n
to the desired limit.
Theorem 4 Under the conditions stated in Theorem 1, the X
m;n
dened above satises
X
m;n
) X as m;n!1, where X is the limiting random variable in Theorem 1.
Algorithm 2: An approximation scheme based on Theorem 2
In this approximation scheme, we again use m to denote the size of the approximation
scheme and n the sample size of the dataset. The larger these parameters, the better for the
approximant X
m;n
to approach the limiting X.
11
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1. Compute statistics ^
i
in (9), c^
i
in (10), p^
i
for i = 1; 2, and
^
F

pool
.
2. For each 0  ~s;
~
t  1, dene the empirical version of
~
K(~s;
~
t) (given in (14)) by
b
~
K(~s;
~
t) =
^
K
n
(
^
F

pool
)
 1
(~s); (
^
F

pool
)
 1
(
~
t)
o
;
where
^
K(s; t), the empirical version of K(s; t), is obtained by replacing all the unknown
quantities in (7) by their estimates. As the estimator
^
F

pool
is piecewise constant, we
interpret its inverse as (
^
F

pool
)
 1
(
~
t)  infft  0 :
^
F

pool
(t) 
~
tg for any
~
t 2 [0; 1]:
3. For a large positive integer m, construct a working matrix A
(m;n)
= (a
u;v
)
mm
such that
a
u;v

1
m
b
~
K(
u
m
;
v
m
) for u; v = 1; : : : ;m:
4. Compute the eigenvalues of matrix A
(m;n)
and rank them from the largest to the smallest
to obtain 
(m;n)
1
 : : :  
(m;n)
m
.
5. Select the rst l eigenvalues and let
X
m;n
=
l^m
X
k=1

(m;n)
k
Z
2
k
where Z
1
;    ; Z
l
are i.i.d. standard normal random variables. Here, l = inffk :

(m;n)
k
=
(m;n)
1
 g where  is a prespecied small constant controlling the accuracy
of approximation.
Since A
(m;n)
is a random matrix, the 
(m;n)
k
s are random quantities. The following theorem
gives the asymptotic results concerning the 
(m;n)
k
s (see the appendix for the detailed proof).
Theorem 5 Under the conditions stated in Theorem 1, lim
m;n!+1

(m;n)
k
= 
k
in probability,
for each k = 1; 2; : : :, where the 
k
are the eigenvalues in (8).
6 Simulation Studies
Simulations were performed to examine the nite sample performance of the proposed test.
Our main objectives are three folds, namely, assessment of the level of the test under varying
12
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sample sizes and degree of censoring, evaluation of the power of the test under the same varying
scenarios, and comparison of our two proposed asymptotical distribution-based algorithms
with the bootstrap procedure adopted by Tamura et al. (2000).
We considered a similar simulation setup utilized by Tamura et al. (2000). Specically, we
set the noncure proportion p
1
= 0:6 in treatment group 1 (for example, the control arm) and
generated the survival times for the noncured patients in this arm by the truncated Weibull
distribution
1  F

1
(t) = [expf (t=)

g   expf (43=)

g=[1  expf (43=)

]; (11)
where we set  = 20 and  = 2. This survival distribution would yield a median time to
death of 16.6 time units with 90% of events occurring within 30 time units among noncured
patients. On the other hand, we simulated the survival times for the noncured patients in
treatment group 2 (e.g. the experiment arm) by
1  F

2
(t) = f1  F

1
(t)g

;
where  = 1 corresponds to the null hypothesis and  6= 1 corresponds to an alternative
hypothesis. In our simulations we set  = 1 when estimating the level of the test and
varied  to be 1.5, 2 and 2.5 when evaluating the power of the test under various alternative
hypotheses. Two dierent proportions of noncure patients in Arm B, p
2
, were considered in
the simulations. We rst let p
2
= 0:6, which was equal to its counterpart in Arm A. In the
second case we set p
2
= 0:9, much higher than its counterpart in Arm B. The censoring times
in both arms were independently simulated by a uniform distribution on [0; c], with c = 60
inducing approximately 50% censoring prior to time 43 and c = 80 inducing approximately
35% censoring prior to time 43. At the opposite extreme, we also considered the case of no
censoring prior to time 43. Same levels of censoring were adopted by Tamura et al. (2000).
Finally, we considered an equal sample size of 100 per treatment group, which is typical in a
two-sample clinical trial.
Table 1 lists the estimates of level and power of test under various conditions, all of which
were based on 1000 data realizations. More specically, for each simulated data set, the
empirical p-values were computed based on the asymptotic distributions approximated by
13
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Algorithms 1 and 2, respectively, and were later dichotomized by whether they fell below
0.05. When applying Algorithms 1 and 2, we chose the mesh size m = 40 and generated
1000 realized values of \X
m;n
" to approximate the desired asymptotic distribution. We set
 = 0:001 when using Algorithm 2. All programming was conducted in the environment of R
and each entry in the table took approximately 2 hours on a mainframe computer.
Based on these simulation results we observed that the size of the test ranged 0.048-0.051
for no censoring, 0.060-0.063 for moderate censoring, and 0.075-0.089 for high censoring, indi-
cating that the test is slightly liberal if censoring is moderate or less and is more considerably
`anticonservative' if censoring is high. Same observations have been documented for the boot-
strap procedure by Tamura et al. (2000). We also noticed, as expected, that the power of the
test increased rapidly as  increased from 1.5 to 2.5 and the power decreased as the amount
of censoring increased. In particular, the powers obtained by the large sample approximation
were slightly better than the powers obtained by the bootstrap procedure reported in Table
II of Tamura et al. (2000). Last we noted that algorithms 1 and 2 yielded nearly identical
sizes and powers.
7 A Data Example
We applied the Cramer-von Mises statistic to analyze the cancer clinical trial described pre-
viously in Section 1. Originally there were three treatment arms in this study. For simplicity,
we only considered the comparison of disease-specic survival between two treatment arms in
this clinical trial. In particular, the disease-specic survival was measured for a total of 184
patients, 95 in the control arm and 89 in the experimental arm. Disease-specic survival is
dened as the time from the start of treatment to the death caused by the disease. Patients
dying from any other causes (for example, traÆc accident or suicide) would be regarded as
being censored at the death dates (see Adelstein et al., 2003).
The top panel of Figure 1 gives the comparison in disease-specic survival by treatment
among all these 184 patients, including those who were cured and non-cured, while the bottom
panel shows the conditional time to disease-specic death among noncured patients.
14
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We estimated from the data that the cured patients were those who had survived from
head and neck cancer for more than 4.2 years, i.e. ^ = 4:2. Using the Kaplan-Meier estimate,
we also estimated that the cure rate in the control arm was q^
1
= 1  
^
F
1
(1 ) = 0:25 with
a 95% condence interval (0:13; 0:37), while the cure rate in the experimental arm was q^
2
=
1  
^
F
2
(1 ) = 0:41 with a 95% interval (0:29; 0:53). The Wald test for equal cure rates
between the two arms, i.e. H
0
: q
1
= q
2
, is marginally signicant (p-value=0.056), favoring
the experimental arm. However, our interest was whether the distribution of disease-specic
survival diers between the two treatment arms among non-cured patients. We applied the
two-sample Cramer-von Mises statistic to test the null hypothesis that the two treatment arms
have the same survival function among the non-cured patients. We calculated the limiting
distribution of the Cramer-von Mises statistic under the null hypothesis by exploiting the
numerical algorithms (Algorithms 1 and 2), where we set m = 40 and n = 184. The resulting
density curves of the limit distribution obtained by both algorithms are displayed in Figure
2. The two curves overlap for the most part and resemble a 
2
distribution. The estimated
quantiles of the distributions by these two algorithms are listed in Table 2 and the leading
eigenvalues of the linear operator in Algorithm 2 are tabulated in Table 3. Based on (6), the
resulting test statistic is 1.16 with a p-value of 0.356 according to the limiting distribution
obtained by Algorithm 1 and 0.362 by Algorithm 2, indicating there is no strong evidence for
a signicant dierence in disease-specic survival between the two treatment arms among the
non-cured patients, though the cure rate in the treatment arm is marginally superior to that
in the control arm.
8 Discussion
In this article, we have developed large sample results and given concrete numerical schemes
for implementing a modied Cramer-Von Mises statistic for two-sample comparisons of con-
ditional survival curves in the presence of cure fractions. We second Tamura et al.'s (2000)
opinion that the cure model is a proper model which separates the survival information into
the proportion of the cured population, and the time to event conditional on being non-cured
patients. Both parts of information are important when evaluating treatment eects in clinical
15
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trials. Our motivation stems from comparisons of conditional survival curves, given that the
tests of cure rates have been well documented in statistical literature (e.g. Gray and Tsiatis,
1989).
Our estimators and numerical schemes can be easily implemented and are fully nonpara-
metric, which is in contrast to the statistics proposed by Koziol and Green (1976) for one-
sample comparisons in the absence of cure fractions and under very specic parametric models
of censorship. On the other hand, as opposed to the bootstrap-based inferential methods pro-
posed by Tamura et al. (2000), our work directly employs large sample results and does not
require any complicated resampling schemes in data analysis, thereby signicantly reducing
the computational burden.
Future research is needed for studying the behavior of the proposed Cramer-von Mises
statistics under the alternative hypothesis, which might facilitate the design of a comparative
clinical trial in a cure rate model. This will also enable one to compare the eÆciency between
the Cramer-von Mises statistics and other commonly used statistics in survival problems (e.g.
log rank tests), under a variety of alternatives.
Related Splus or R programs for computing the proposed Cramer-von Mises test statistic
and its distribution under the null hypothesis are available upon request.
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Appendix: Technical Details
A Convergence Theorem on Stochastic Integrals
The following is extracted from Theorem 2.2 in Kurtz and Protter (1991), of which we
have made repeated usage in our proofs.
Theorem 6 For each n, let (X
n
; Y
n
) be an fF
n
t
g-adapted process with paths in D
R
2
[0;  ].
Let Y
n
= M
n
+ A
n
, where M
n
(t) is an fF
n
t
g-martingale and A
n
(t) be a process with nite
variation. Suppose for each t,
sup
n
E
n
[M
n
](t) + T
t
(A
n
)
o
<1; (12)
where T
t
(A
n
) denotes the total variation of A
n
up to time t and [M ](t) denotes the quadratic
(or called optional) variation process for a local martingale M() (see, e.g. Andersen et al.,
1993, p.69).
Suppose (X
n
; Y
n
)) (X;Y ) in the Skorohod topology on D
R
2
[0; T ], then Y is a semimartin-
gale with respect to a ltration to which (X;Y ) are adapted and

X
n
(t); Y
n
(t);
Z
t
0
X
n
(s )dY
n
(s)

)

X(t); Y (t);
Z
t
0
X(s )dY (s)

(13)
in the Skorohod topology. If (X
n
; Y
n
) ! (X;Y ) in probability, then (13) also converges in
probability.
Proof of Theorem 2
From (7), 0  K(s; t) = K(t; s)  sup
0s;t
K(s; t) <1. Hence, T is self-adjoint by the
symmetry of K; T is positive since it maps nonnegative functions to nonnegative functions;
T is compact because K is square integrable. Specically,
R

0
R

0
K
2
(s; t)F (ds)F (dt) < 1
(in fact, K is even bounded). Therefore, T maps a set of uniformly bounded sequence of
functions to a compact sequence of functions in the Hilbert space (Dunford and Schwartz,
1958). Hence, spectrum theory for linear compact operators implies that
K(s; t) =
1
X
k=1

k
f
k
(s)f
k
(t)
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almost everywhere by the product measure F

(ds)  F

(dt), where f
k
 0g 2 `
2
and
ff
k
()g is the orthonormal basis in L
2
([0;  ]). Consequently, dene a Gaussian process H(t) =
P
1
k=1
p

k
f
k
(t)Z
k
so that
E
n
H(t)H(s)
o
=
1
X
k=1

k
f
k
(t)f
k
(s = K(s; t) = E
n
G(t)G(s)
o
:
Therefore, the two Gaussian processes H() and G() agree in distribution, and
Z

0
G
2
(t )dF

(t)
D
=
Z

0
H
2
(t )dF

(t)
=
X
i
X
j
p

i

j
Z
i
Z
j
Z

0
f
i
(t)f
j
(t)dF

(t)
=
X
k

k
Z
2
k
:
Since T is a self-adjoint compact positive linear integral operator, there are at most count-
ably many 
k
 0 and the only possible point of accumulation for 
k
is 0 (see, e.g. Dunford
and Schwartz, 1958). Without loss of generality, we may assume 
1
 
2
 : : :  0. 
Proof of Theorem 3
The Glivenko-Cantelli theorem implies that the empirical distribution ^
i
(s)! P (V
ij
 s)
uniformly on [0;  ] and this convergence is joint with the convergence in probability of
^
F
i
to
F
i
. Thus, a direct application of Theorem 6 yields the result. 
Proof of Theorem 4
Joint with the convergence in probability (in the Skorohod topology) of p^
i
! p
i
and
^
F

pool
! F

, and because c
i
is continuous, then W
m;n
i
(t)) W
i
fc
i
(t)g: This result follows from
the martingale central limit theorem. Therefore, jointly we have G
m;n
(t)) G(t):
Note that
^
F

pool
(t) satises assumption (12). Applying Theorem 6, X
m;n
) X: 
Justication of T and
~
T Having Same Eigenvalues in Section 3
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For simplicity, we assume that f(t) > 0 whenever t 2 [0;  ]. Therefore, F

is strictly
increasing and absolutely continuous on [0;  ]. Dene a one-to-one correspondence
F

(s) = ~s; F

(t) =
~
t;

L
2
([0; 1]); h; i

3
~
f(~s) = f(s) 2

L
2
([0;  ]; (; ))

;
and dene
~
K(~s;
~
t) = K(s; t) = K

(F

)
 1
(~s); (F

)
 1
(
~
t)

: (14)
Let (
~
T
~
f)(
~
t) =
R
1
0
~
K(~s;
~
t)
~
f(~s)d~s: Then
~
T is a compact positive linear integral operator on

L
2
([0; 1]); h; i

and the 
k
s are also the eigenvalues for
~
T . That is, 
k
~
f
k
=
~
T
~
f
k
: 
Proof of Theorem 5
First note that the eigenvalues of the matrix A
(m;n)
in Algorithm 2 are equal to those of
the (discretized) linear operator
~
T
m
in L
2
([0; 1]),
~
T
m
~
f(
~
t) =
Z
1
0
b
~
K
m
(~s;
~
t)
~
f(~s)d~s;
~
f 2 L
2
([0; 1]);
where
b
~
K
m
(~s;
~
t) =
^
~
K(
u
m
;
v
m
) if
u  1
m
 ~s <
u
m
;
v   1
m

~
t <
v
m
for some u; v 2 f1; : : : ;mg.
By the Cauchy-Schwartz inequality, we bound the norm dierence between linear operators
~
T
m
and
~
T as follows:
k
~
T
m
 
~
T k  sup
k
~
fk
L
2
=1
k(
~
T
m
 
~
T )
~
fk
L
2


Z
1
0
Z
1
0
(
^
~
K
m
 
~
K)
2
(~s;
~
t)d~sd
~
t

1=2


Z
1
0
Z
1
0
(
^
~
K
m
 
b
~
K)
2
(~s;
~
t)d~sd
~
t

1=2
+

Z
1
0
Z
1
0
(
b
~
K  
~
K)
2
(~s;
~
t)d~sd
~
t

1=2
(15)
For any xed n,
b
~
K(~s;
~
t) is a bounded piece-wise constant function with nite discontinuities,
so the rst term in (15) converges to 0 as the mesh size m!1. For the second term in (15),
notice that

Z
1
0
Z
1
0
(
b
~
K  
~
K)
2
(~s;
~
t)d~sd
~
t

1=2
 sup
0~s1;0
~
t1
j
b
~
K(~s;
~
t) 
~
K(~s;
~
t)j:
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Then by the consistency of
^
F

pool
to F

, c^
i
to c
i
,
^
K to K, and by the continuity of K, the
continuous mapping theorem gives
lim
n!+1
sup
0~s1;0
~
t1
j
b
~
K(~s;
~
t) 
~
K(~s;
~
t)j = 0 in probability.
Thus lim
m;n!+1
k
~
T
m
 
~
T k = 0 in probability. The desired result then follows from Theorem
4.10 in Chapter 5 of Kato (1980). 
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Table 1: Rejection rates for the Cramer-von Mises statistic with 1000 realizations for each
parameter setting. The sample size is 100 per treatment group.
censoring percentage rejection rate
p
1
p
2
prior to time 43  algorithm 1 algorithm 2 bootstrap(*)
Null hypothesis cases
0.6 0.6 0 1.0 0.051 0.051 0.048
0.6 0.6 35 1.0 0.063 0.063 0.056
0.6 0.6 50 1.0 0.086 0.089 0.082
0.6 0.9 0 1.0 0.048 0.047 0.051
0.6 0.9 35 1.0 0.063 0.060 0.065
0.6 0.9 50 1.0 0.075 0.076 0.064
Alternative hypothesis cases
0.6 0.6 0 1.5 0.477 0.478 0.425
0.6 0.6 35 1.5 0.410 0.414 0.365
0.6 0.6 50 1.5 0.404 0.411 0.300
0.6 0.9 0 1.5 0.541 0.546 0.474
0.6 0.9 35 1.5 0.472 0.470 0.416
0.6 0.9 50 1.5 0.421 0.424 0.291
0.6 0.6 0 2.0 0.894 0.894 0.895
0.6 0.6 35 2.0 0.821 0.827 0.817
0.6 0.6 50 2.0 0.807 0.802 0.682
0.6 0.9 0 2.0 0.941 0.940 0.930
0.6 0.9 35 2.0 0.898 0.894 0.878
0.6 0.9 50 2.0 0.838 0.832 0.754
0.6 0.6 0 2.5 0.988 0.989 0.988
0.6 0.6 35 2.5 0.977 0.974 0.981
0.6 0.6 50 2.5 0.963 0.963 0.914
0.6 0.9 0 2.5 0.996 0.996 0.997
0.6 0.9 35 2.5 0.981 0.985 0.985
0.6 0.9 50 2.5 0.977 0.975 0.945
* adopted from Table II in Tamura et al. (2000).
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Table 2: Percentiles of the Limit Distribution of the Cramer-von Mises Statistics Obtained
by Two Algorithms.
5% 10% 15% 20% 25% 30% 35% 40% 45%
Alg. 1 0.2635 0.3374 0.3993 0.4531 0.5089 0.5680 0.6328 0.7010 0.7758
Alg. 2 0.2600 0.3308 0.3899 0.4510 0.5110 0.5698 0.6339 0.7045 0.7846
50% 55% 60% 65% 70% 75% 80% 85% 90% 95%
0.8573 0.9543 1.0647 1.1864 1.3283 1.4919 1.7083 2.0144 2.4629 3.2606
0.8638 0.9635 1.0717 1.1923 1.3287 1.5003 1.7326 2.0434 2.4519 3.2715
Table 3: Leading Eigenvalues of the Linear Operator Used in Algorithm 2.
7.181848e-01 1.953676e-01 7.928266e-02 4.648866e-02 2.991972e-02
2.083118e-02 1.550592e-02 1.218492e-02 9.903118e-03 8.482065e-03
6.716481e-03 5.820127e-03 4.730430e-03 3.897105e-03 3.749634e-03
3.389445e-03 2.913652e-03 2.697358e-03 2.510337e-03 2.327357e-03
2.083282e-03 2.010754e-03 1.681561e-03 1.554187e-03 1.511168e-03
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Figure 2: Density Curves of Cramer-von Mises Statistic
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